In major news released December 3, 2015, Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) stated that it had signed a Letter of Intent (LOI) regarding a future strategic alliance with Regience K.K. for Japan and potentially other Asian countries. Cynata owns the rights to a novel mesenchymal stem cell (MSC) manufacturing process that can produce an unlimited quantity of MSCs from induced pluripotent stem cells (iPSCs) derived from a single donor. This Cymerus technology™ allows for the consistent, scalable production of MSCs in essentially unlimited quantities. By allowing for cost-effective production of clinical grade MSCs, the technology also solves one of the major hurtles currently limiting cell therapy procedures, which is their “sky-high” cost.
The news caught the attention of regenerative medicine investors, causing Cynata’s stock price to jump more than 10% to 40 cents. [Read more…]